LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
1W: -6.1%
1M: -1.6%
3M: +56.4%
YTD: +118.3%
$44.63
-1.62 (-3.50%)
Weekly Expected Move ±7.5%
$38
$41
$45
$48
$51
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3B
52W Range13.36-50.16
Volume208,368
Avg Volume285,808
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEOHeather D. Turner
Employees49
SectorHealthcare
IndustryBiotechnology
IPO Date2025-09-11
Websitelbpharma.us
One Pennsylvania Plaza
New York, NY 10119
US
New York, NY 10119
US
212 605 0300
About LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Latest News
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX
LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
Recent Insider Trades
No insider trades found